S M Offer
Overview
Explore the profile of S M Offer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nie Q, Shrestha S, Tapper E, Trogstad-Isaacson C, Bouchonville K, Lee A, et al.
Clin Pharmacol Ther
. 2017 Mar;
102(4):662-670.
PMID: 28295243
Dihydropyrimidine dehydrogenase (DPD; DPYD gene) variants have emerged as reliable predictors of adverse toxicity to the chemotherapy agent 5-fluorouracil (5-FU). The intronic DPYD variant rs75017182 has been recently suggested to...
2.
Elraiyah T, Jerde C, Shrestha S, Wu R, Nie Q, Giama N, et al.
Clin Pharmacol Ther
. 2016 Oct;
101(3):382-390.
PMID: 27727460
Clinical studies have identified specific genetic variants in dihydropyrimidine dehydrogenase (DPD; DPYD gene) as predictors of severe adverse toxicity to the commonly used chemotherapeutic 5-fluorouracil (5-FU); however, these studies have...
3.
4.
Witzig T, Hu G, Offer S, Wellik L, Han J, Stenson M, et al.
Leukemia
. 2013 Aug;
28(1):147-54.
PMID: 23979523
Protein tyrosine phosphatases such as PTPN6 can be downregulated in various neoplasms. PTPN6 expression by immunohistochemistry in 40 diffuse large B-cell lymphoma (DLBCL) tumors was lost or suppressed in 53%...
5.
Offer S, Lee A, Mattison L, Fossum C, Wegner N, Diasio R
Clin Pharmacol Ther
. 2013 Apr;
94(1):158-66.
PMID: 23588312
5-Fluorouracil (5-FU) is used to treat many aggressive cancers, such as those of the colon, breast, and head and neck. The responses to 5-FU, with respect to both toxicity and...